For laboratory research use only. This page summarizes public scientific literature. It is not medical advice and does not describe or endorse human, clinical, or veterinary use.
Chemistry & identity
| CAS Number | n.a. |
|---|---|
| Molecular Formula | n.a. |
| Molecular Weight | n.a. g/mol |
| PubChem CID | n.a. |
Peptide sequence
n.a.
Research context
Blend, so no single CAS/formula/MW/sequence. The FDA docket peptide list (FDA-2024-N-4777) documents "CJC 1295 without DAC + Ipamorelin" combination products at 1-2 mg of each per mL. Constituent chemistry: CJC-1295 without DAC = CAS 863288-34-0, C152H252N44O42, 3367.9 g/mol (PubChem CID 56841945); ipamorelin = CAS 170851-70-4, C38H49N9O5, 711.9 g/mol (PubChem CID 9831659).
Selected research references
Published peer-reviewed literature on CJC-1295 without DAC 5mg + IPA5mg. Provided for research-context purposes only; CC Peptides does not make claims about outcomes in humans.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
- Ipamorelin, the first selective growth hormone secretagogue
CJC-1295 without DAC 5mg + IPA5mg for laboratory research
CC Peptides supplies CJC-1295 without DAC 5mg + IPA5mg as a lyophilized reference material with a third-party COA. Ships from California.
View product page →